Funding
← Back to your selection

Duquesne Family Office

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Enterprise software · Jan 1, 2026

Duquesne Family Office is the family-office investor identified by Precision Neuroscience and Cellares.

Recorded funding activity

Its recorded company activity also includes Epicrispr’s epigenetic medicines, Ratio’s radiopharmaceuticals and SonoThera’s ultrasound-mediated genetic-medicine delivery. These are separate therapeutic approaches. The institutional record remains distinct from Stanley Druckenmiller’s personal investment identity.

Sources
Rounds participated in
1
Confirmed lead rounds
—
1 roles undisclosed
New companies
1
First participation on record · 0 follow-on
Funding in participating rounds
$90M
1 disclosed · full round size, not this investor’s share

By stage

Series C+1

By primary sector

Biotech1

By country

United States1

Rounds

1 in this selection